Data Sheet | April 27, 2026
ResistanceSeek™: Quantify cellular resistance pathways in human tumors
Get the Resource
Seek Products - Request
Request a Seek study using the form.
"*" indicates required fields
Sapient’s ResistanceSeek enables deep, direct, and comprehensive tumor resistance profiling by directly measuring the protein networks that drive therapeutic resistance in human tumors.
Oncology drug development rarely fails because a target lacks biological relevance. More often, it stems from incomplete understanding or indirect measurement of resistance biology. Across modern therapeutic modalities, including kinase inhibitors, ADCs, T-cell engagers, radioligand therapies, and immuno-oncology agents, tumors adapt through coordinated resistance programs that restore survival under therapeutic pressure. However, these critical resistance mechanisms are driven at the protein level and therefore rarely captured by conventional genomic approaches.
We built ResistanceSeek to address this challenge by directly quantifying resistance-associated protein networks in human tumors using a mass spectrometry-based discovery proteomics workflow.
What dimensions of resistance biology can be characterized via ResistanceSeek?
Historically, resistance has been treated as a retrospective explanation for drug failure. In modern oncology development, resistance must be viewed as a measurable and actionable variable. ResistanceSeek shifts development from genomic inference to functional protein measurement across the pathways that define resistance in human tumors – enabling mechanism-driven decision-making. This tumor resistance profiling encompasses:
- Pathway reactivation and bypass signaling
- Survival and anti-apoptotic protein upregulation
- Target modulation and antigen loss
- DNA damage response and repair activation
- Immune evasion and tumor microenvironment adaptation
Importantly, ResistanceSeek is optimized for both fresh-frozen and FFPE human tumor samples, unlocking the ability to measure resistance biology in both prospective studies and archived clinical samples.
What new insights can I gain from tumor resistance profiling at the protein level?
Modern oncology development requires resistance to be defined as a measurable, functional state. With ResistanceSeek, resistance is not identified after tumors have already adapted, but rather proactively quantified to be compared and acted upon as resistance mechanisms emerge.
The workflow applies deep discovery proteomics to comprehensively profile coordinated protein networks through which resistance mechanisms are executed, including MAPK and PI3K/AKT/mTOR pathway reactivation, upregulation of anti-apoptotic proteins, activation of DNA repair pathways, initiation of immune evasion programs, and more.
Download the white sheet to explore more on how ResistanceSeek maps the functional resistance proteome with unmatched depth and precision.
What development questions can I answer with ResistanceSeek for tumor resistance profiling?
By directly profiling the protein networks that execute resistance programs, ResistanceSeek enables prospective insight into how tumors evade therapeutic pressure, supporting mechanism‑driven trial design, rational combination strategies, and improved patient stratification. Oncology R&D teams can answer questions such as:
| Development Question | ResistanceSeek Insight |
|---|---|
| Why are patients failing therapy despite target engagement? | Identification of activated resistance pathways |
| Which compensatory pathways are driving escape? | Quantitative pathway activation profiling |
| How should combination therapies be selected? | Identification of dominant resistance mechanisms |
| Can archived trials reveal responder subsets? | Proteomic profiling of FFPE cohorts |
| How can patient selection be improved? | Functional stratification based on resistance biology |
ResistanceSeek is offered as a standalone workflow or within Sapient’s broader Tumor Protein Mapping Platform which also includes SurfaceSeek™ to identify druggable tumor cell surface proteins, SignalingSeek™ to measure signaling pathway activation, and ImmuneSeek™ to map tumor immune biology – directly in fresh-frozen and FFPE human tumors.
Move from post-hoc analysis of resistance to prospective insights – get started today
For drug developers seeking to understand and overcome resistance, ResistanceSeek provides direct biological insight into therapeutic failure and adaptation.
Use the form to request a ResistanceSeek or provide more information about your program. You can also email discover@sapient.bio to set up a time to talk about your needs.
Get the Resource
Seek Products - Request
Request a Seek study using the form.
"*" indicates required fields